Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,372 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05300282RecruitingPhase 1/Phase 2
Atezolizumab plus chemotherapy for Hodgkin lymphoma after relapse
This trial studies whether adding atezolizumab to a chemotherapy-type treatment (the BEGEV regimen) can shrink Hodgkin lymphoma that has come back or did not respond. It may help people who have only had one prior whole-system (systemic) treatment and can still receive stem cell transplant (ASCT).
Alessandria, AlessandriaAges 18–60 - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05338931RecruitingPhase 1/Phase 2
AT101 for relapsed or refractory B-cell lymphoma patients
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
SeoulAges 19 years+ - NCT05341557RecruitingPhase 1
First-in-human drug study for advanced cancers and lymphoma
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Chaoyang, Beijing MunicipalityAges 18 years+ - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05355051RecruitingPhase 2
Azacitidine plus pembrolizumab for Hodgkin lymphoma after relapse
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
Houston, TexasAges 1 year+ - NCT05357651RecruitingPhase 1
LB1410 study for advanced lung, colon, and other cancers
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05366569Recruiting
CAR T-cell therapy for certain blood cancers after relapse
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
BresciaAges 18–70 - NCT05388006RecruitingPhase 2
Testing three medicines for Richter transformation in CLL/SLL
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
Palo Alto, CaliforniaAges 18 years+ - NCT05436223RecruitingPhase 2
CD19 CAR-T for certain relapsed or refractory lymphoma
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT05477264RecruitingPhase 2
Tislelizumab with radiation for early nasal lymphoma
This trial tests whether adding a medicine called tislelizumab to radiation works better than radiation alone for newly diagnosed nasal (nasal-type) NK/T-cell lymphoma. If you qualify, it may help control the cancer and improve outcomes by using both treatments together.
SeoulAges 19 years+ - NCT05481437Recruiting
Surveying brentuximab for children with Hodgkin lymphoma
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
Tokyo, TokyoAges Up to 18 years - NCT05518851Recruiting
Study of treatments and outcomes for primary skin lymphoma
This study looks at what treatments work for people with primary cutaneous lymphoma, and how patients do over time. It uses real patient information from participating hospitals to understand outcomes after diagnosis.
Beijing, Beijing MunicipalityAges Any age - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05541341Recruiting
Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Minas Gerais, Belo HorizonteAges birth–100 years - NCT05595577Recruiting
Personalized exercise program to improve fitness during cancer care
This trial tests whether a tailored, home-based exercise plan can improve exercise capacity (how far and how safely you can be active) in people receiving cancer treatments that may affect the heart. It may help you build safer stamina while monitoring your heart health.
Winston-Salem, North CarolinaAges 18–85 - NCT05607498RecruitingPhase 1
First study of EMB-07 for advanced cancers or lymphoma
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
Frankston, VictoriaAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05616325Recruiting
Fertility follow-up for women after lymphoma chemotherapy
This study looks at long-term ovarian (egg-producing) fertility after chemotherapy for lymphoma, about 5 years after treatment ends. It may help doctors better understand pregnancy potential and guide future family-planning care.
LilleAges 18–45 - NCT05623982RecruitingPhase 1/Phase 2
Study drug for lymphoma that has returned or did not respond
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
Beijing, Beijing MunicipalityAges 18–75 - NCT05635162RecruitingPhase 2
Zanubrutinib plus rituximab for slow-growing mantle cell lymphoma
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
DerbyAges 18 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,372 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.